108 related articles for article (PubMed ID: 36077308)
21. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
22. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
Spagnolo F; Ghiorzo P; Queirolo P
Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
24. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
Corrales E; Levit-Zerdoun E; Metzger P; Mertes R; Lehmann A; Münch J; Lemke S; Kowar S; Boerries M
Cell Commun Signal; 2022 Nov; 20(1):187. PubMed ID: 36434616
[TBL] [Abstract][Full Text] [Related]
25. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.
Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F
Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
27. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
28. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
29. Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness.
Tadijan A; Precazzini F; Hanžić N; Radić M; Gavioli N; Vlašić I; Ozretić P; Pinto L; Škreblin L; Barban G; Slade N; Ciribilli Y
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680379
[TBL] [Abstract][Full Text] [Related]
30. Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.
Basu S; Dong Y; Kumar R; Jeter C; Tang DG
Semin Cancer Biol; 2022 Jan; 78():90-103. PubMed ID: 33979674
[TBL] [Abstract][Full Text] [Related]
31. The metastasis suppressor protein NM23-H1 modulates the PI3K-AKT axis through interaction with the p110α catalytic subunit.
Pennino FP; Murakami M; Zollo M; Robertson ES
Oncogenesis; 2021 Apr; 10(4):34. PubMed ID: 33931587
[TBL] [Abstract][Full Text] [Related]
32. Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma.
Fattore L; Mancini R; Ciliberto G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202944
[TBL] [Abstract][Full Text] [Related]
33. Plasticity of cancer cell invasion: Patterns and mechanisms.
Wu JS; Jiang J; Chen BJ; Wang K; Tang YL; Liang XH
Transl Oncol; 2021 Jan; 14(1):100899. PubMed ID: 33080522
[TBL] [Abstract][Full Text] [Related]
34. Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
Pamidimukkala N; Puts GS; Kathryn Leonard M; Snyder D; Dabernat S; De Fabo EC; Noonan FP; Slominski A; Merlino G; Kaetzel DM
Br J Cancer; 2021 Jan; 124(1):161-165. PubMed ID: 33024267
[TBL] [Abstract][Full Text] [Related]
35. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment.
Tang Y; Durand S; Dalle S; Caramel J
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759677
[TBL] [Abstract][Full Text] [Related]
36. Mechanical interplay between cell shape and actin cytoskeleton organization.
Schakenraad K; Ernst J; Pomp W; Danen EHJ; Merks RMH; Schmidt T; Giomi L
Soft Matter; 2020 Jul; 16(27):6328-6343. PubMed ID: 32490503
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
